Evidence map›Paper›PMID 38700272›Full record

ArticleClinical and translational science2024

Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.

Adam Dickinson, Yong Liu, Artem Uvarov, Thomas Peyret, J F Marier, Curtis Chin, Jonathan Q Tran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adam DickinsonMirati Therapeutics Inc, San Diego, California, USA.ORCID 0000-0002-9246-7753
Yong LiuMirati Therapeutics Inc, San Diego, California, USA.
Artem UvarovCertara Drug Development Solutions, Princeton, New Jersey, USA.ORCID 0000-0003-4568-3143
Thomas PeyretCertara Drug Development Solutions, Princeton, New Jersey, USA.ORCID 0000-0003-3723-4006
J F MarierCertara Drug Development Solutions, Princeton, New Jersey, USA.ORCID 0000-0001-9820-5116
Curtis ChinMirati Therapeutics Inc, San Diego, California, USA.
Jonathan Q TranMirati Therapeutics Inc, San Diego, California, USA.ORCID 0000-0002-7187-7307

Funding

Mirati Therapeutics Inc.
6 · The paper itself

Abstract

Sitravatinib (MGCD516) is an orally available, small molecule, tyrosine kinase inhibitor that has been evaluated in patients with advanced solid tumors. Concentration-corrected QT interval (QTc; C-QTc) modeling was undertaken, using 767 matched concentration-ECG observations from 187 patients across two clinical studies in patients with advanced solid malignancies, across a dose range of 10-200 mg, via a linear mixed-effects (LME) model. The effect on heart rate (HR)-corrected QT interval via Fridericia's correction method (QTcF) at the steady-state maximum concentration (C

Indexed as

ElectrocardiographyHeart RateNeoplasmsAdultAgedAged, 80 and overAntineoplastic AgentsDose-Response Relationship, DrugFemaleHumansLong QT SyndromeMaleMiddle AgedModels, BiologicalProtein Kinase InhibitorsYoung AdultAntineoplastic AgentsProtein Kinase Inhibitors

Identifiers

PMID38700272
PMCPMC11067505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.